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ABSTRACT
Objective: To compare the effect of inhaled budesonide
given daily or as-needed on mild persistent childhood
asthma.
Patients, design and interventions: 176 children aged
5–10 years with newly detected asthma were randomly
assigned to three treatment groups: (1) continuous
budesonide (400 mg twice daily for 1 month, 200 mg
twice daily for months 2–6, 100 mg twice daily for
months 7–18); (2) budesonide, identical treatment to
group 1 during months 1–6, then budesonide for
exacerbations as needed for months 7–18; and (3)
disodium cromoglycate (DSCG) 10 mg three times daily
for months 1–18. Exacerbations were treated with
budesonide 400 mg twice daily for 2 weeks.
Main outcome measures: Lung function, the number of
exacerbations and growth.
Results: Compared with DSCG the initial regular
budesonide treatment resulted in a significantly improved
lung function, fewer exacerbations and a small but
significant decline in growth velocity. After 18 months,
however, the lung function improvements did not differ
between the groups. During months 7–18, patients
receiving continuous budesonide treatment had signifi-
cantly fewer exacerbations (mean 0.97), compared with
1.69 in group 2 and 1.58 in group 3. The number of
asthma-free days did not differ between regular and
intermittent budesonide treatment. Growth velocity was
normalised during continuous low-dose budesonide and
budesonide therapy given as needed. The latter was
associated with catch-up growth.
Conclusions: Regular use of budesonide afforded better
asthma control but had a more systemic effect than did
use of budesonide as needed. The dose of ICS could be
reduced as soon as asthma is controlled. Some children
do not seem to need continuous ICS treatment.
Most children with asthma experience their first
symptoms before 7 years of age.
1 Studies of adults
and children with asthma have shown that some
functional reversibility may be lost if anti-inflam-
matory treatment is postponed.
2–4 The anti-asth-
matic effect of inhaled corticosteroids (ICS) has
been demonstrated in long-term intervention
studies,
5–10 and these findings have led to ICS
becoming the mainstay of treatment for persistent
asthma.
11 12 However, high-dose ICS may have
systemic effects such as reduction in height
velocity
6–8 13 and adrenal insufficiency.
14
In an 18-month intervention, we compared two
budesonide therapeutic regimens with a control
group treated with a fixed dose of disodium
cromoglycate (DSCG). The study was designed to
evaluate the anti-asthmatic efficacy and systemic
effect of daily versus as-needed budesonide in the
treatment of early, mild persistent asthma in
children.
METHODS
Children between 5 and 10 years, all Caucasians,
were included, if they presented symptoms such as
wheezing, prolonged cough or shortness of breath,
suggesting asthma for at least 1 month before
entry into the study, and significant bronchial
reversibility. The latter was defined as at least a
20% diurnal variation in repeatable peak expiratory
flow (PEF) measurements, or at least a 15%
increase in PEF at least three times within 2 weeks
of home recording, or at least a 15% increase in
forced expiratory volume in 1 second (FEV1)
15 min after inhalation of a b2-agonist, or at least
a 15% decline in FEV1 in an outdoor exercise test in
the clinic.
15 According to the symptoms and lung-
function tests, the majority of children could be
categorised as having mild persistent asthma.
16
Children with acute asthma, an FEV1,50%
17 and
with treatment during the preceding 2 months
with ICS, cromones, leukotriene modifiers or long-
acting b2-agonists were excluded. The total cumu-
lative doses of previously used ICS must not have
exceeded 36 mg, 12 mg of nasal corticosteroids or
oral doses equivalent to 200 mg prednisolone.
The 18-month study was of a controlled,
randomised, double-blind, parallel-group, single-
centre design including a 2-week run-in period.
Two blinded treatment regimens were initiated
with inhaled budesonide via a dry-powder inhaler
(Pulmicort Turbuhaler, AstraZeneca, Lund,
Sweden), and one open-label treatment regimen
was initiated with DSCG via a pressurized metered
dose inhaler (pMDI; Lomudal with Fisonair
spacer, Aventis Pharma, Holmes Chapel, UK).
Patients were randomised as to treatment in
balanced blocks as generated by a computer
program. During the 2-week run-in period, all
enrolled patients received a short-acting b2-agonist,
terbutaline (Bricanyl Turbuhaler, 0.25 mg/dose,
AstraZeneca, Lund, Sweden) as needed. After the
run-in period, children were assigned to one of
three treatment groups: (1) continuous budesonide
group, receiving budesonide (400 mg twice daily for
the first month, then 200 mg twice daily for
5 months) followed by low-dose budesonide
(100 mg twice daily for 12 months); (2) budeso-
nide/placebo group, where patients received
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6 months followed by placebo for 12 months; and (3) DSCG
control group, where patients received DSCG 10 mg three-times
daily for 18 months (fig 1).
All patients were given rescue medication of terbutaline
0.25 mg per dose as needed. For all groups, during exacerbations
of asthma, study medication was replaced by budesonide 400 mg
twice daily for 2 weeks. Children were withdrawn from the
study and given individually tailored therapy if treatment of
their exacerbations remained insufficient.
The study was performed in accordance with the Declaration
of Helsinki, and was approved by the local ethics committee.
Written, informed consent was obtained from each patient’s
parent(s) or legal guardian and from the patient.
For the budesonide treatment groups, treatment compliance
was recorded using a home spirometer (Vitalograph Data
Storage spirometer, Vitalograph, Buckingham, UK), which
recorded the peak inspiratory flow via Turbuhaler (PIFTBH)
each time a dose of the drug was taken.
18 In the DSCG group,
the returned pMDI drug canisters were counted and weighed
every 3 months.
The primary efficacy variable was morning PEF. Secondary
efficacy variables were FEV1, the number of asthma exacerba-
tions, asthma-free days and rescue medication use. Morning PEF
was measured daily at home. FEV1 was measured at the clinic
visit every third month. An asthma exacerbation was defined as
an increase in symptoms that were not controlled with six doses
of rescue terbutaline per 24 h that caused the parent to contact
the clinic. All parents were provided with a 24-h emergency
telephone number. At the clinic, patients were examined by a
paediatrician, who decided whether an exacerbation had
occurred and, if so, replaced the regular medication with a 2-
week course of budesonide 400 mg twice daily. The treatment of
an exacerbation was considered insufficient if the symptoms did
not subside during the 2-weeks’ budesonide inhalations that
caused the parent to contact the clinic. If an oral or parenteral
corticosteroid was needed, the child received individual treat-
ment and was withdrawn from the study.
All patients recorded their PEF rate daily, as measured by a
home spirometer, before taking study medication. They
also recorded their asthma symptoms using a visual analogue
scale (0–10) and use of rescue medication. An asthma-free
day was defined as a 24-h period without use of rescue
medication and with a symptom score ,2. Standard laboratory
spirometry (Spirotrac III, Vitalograph) was performed at all
clinic visits.
19
The primary indicator of systemic effect was the standing-
height velocity, which was measured at each clinic visit using a
stadiometer (Holtain, Crymych, UK) following a standardised
procedure. Children with Tanner stage I-II at baseline were
included. Tanner stage of sexual development is scored from I
(pre-adolescence) to V (adult characteristics).
20 Standing height
was compared with Finnish reference values.
21 Other indicator
was body mass index (kg/m
2).
The sample size was determined by power calculations for
morning PEF. A clinically significant change was assumed to be
40 l/min over an 18-month period. With 60 patients per
treatment group, there was a 90% chance of detecting a
difference of 24 l/min between treatments. The analysis of
growth was performed on the complete study population
(excluding pubertal children). All other variables were analysed
using intention-to-treat principles, that is, all patients who had
taken at least one dose of study medication and had data for the
required period(s). Withdrawn patients were handled using last
value extended, within period. Comparisons between the
combined budesonide groups and the DSCG group were made
for months 1–6; from 7–18 months comparisons were made
between all three groups.
For most variables, treatment groups were compared using
analysis of variance (ANOVA) with fixed factor treatment and
baseline values as covariates. For growth variables, sex was
included as an additional factor in the analysis. Time to first
asthma exacerbation and time to withdrawal were compared
using the log-rank test. The number of exacerbations was
compared using a Poisson regression model with fixed factor
treatment, time in study as an offset and adjustments made for
overdispersion.
RESULTS
A total of 176 children were enrolled in the study. There were
no significant differences between treatment groups in any
baseline measures (table 1). During the run-in period, the mean
use of terbutaline was about one dose every 2 days in all
treatment groups. Three patients were withdrawn because of
asthma deterioration during continuous budesonide treatment
after 6 months of the study. In the budesonide /placebo group,
nine children were withdrawn because of asthma deterioration,
all after 6 months of treatment. In the DSCG group, eight
children were withdrawn during the first 6 months of the
study, and four children thereafter (continuous budesonide
versus DSCG; p=0.026). One child on placebo and one child on
DSCG were hospitalised, because of deterioration in their
asthma. The numbers of patients withdrawn from the
treatment groups for reasons not related to asthma were three
in the continuous budesonide group, three in the budesonide/
placebo group, and four in the DSCG group. The flow of the
participants through the trial is presented in the fig 2. The mean
treatment compliance for the three treatment groups decreased
linearly from an initial level of ,90% to a mean level of ,60%
towards the end of the study. This was matched by a
subsequent reduction in the amount of drug used during the
study. Children in the continuous budesonide and budesonide/
placebo treatment groups achieved a mean PIFTBH of 60 l/min
during the study period.
After 6 months, the morning PEF values (l/min) of the
budesonide groups improved by 6.6% and by 6.1% in the DSCG
group. After 18 months, the increase was 10.3% in the
continuous, 10.0% in the budesonide/placebo and 12.5% in
Figure 1 Study design. The daily dose
of budesonide was divided into two
doses, DSCG into three doses.
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between the groups at any time point. After 6 months of
treatment, improvement in FEV1 in litres in the clinic was
significantly greater in the budesonide groups than in the DSCG
group (9.6 versus 5.9%; p=0.012). From baseline to 18 months,
FEV1 improved by 18.2%, in the continuous, by 16.9% in the
budesonide/placebo and by 17.3% in the DSCG group without
any significant differences.
Over the 18-month study period, 364 exacerbations of asthma
were recorded in 133 patients. During the first 6 months of
treatment, children receiving budesonide had significantly fewer
exacerbations compared with children in the DSCG group
(table 2). During months 7–18, the continuous budesonide
group (ie, children on low-dose budesonide) had significantly
fewer exacerbations than either the budesonide/placebo group
(ie, children given the placebo) or the DSCG group (table 2).
The median time to the first exacerbation was significantly
longer for both the continuous budesonide (344 days) and the
budesonide/placebo (268 days) groups compared with the
DSCG group (78 days) (p,0.001 for each) (fig 3). After
180 days, the median time to the next exacerbation was
233 days for the continuous budesonide group, 138 days for
Figure 2 The flow of the participants through the trial.
Table 1 Baseline characteristics of treatment groups*
Treatment group Continuous budesonide (n=58) Budesonide/placebo (n=58) Disodium cromoglycate (n=60)
Age (years) 7.0 (5 to 10) 6.7 (5 to 10) 6.9 (5 to 10)
Male (%) 59 66 54
Tanner pubertal stage I/II 58/1 58/1 61/2
Standing height (cm) 128.4 (108 to157) 125.1 (106 to 148) 125.6 (105 to 148)
Standing height, standard deviation scores
(SDS)
0.04 (20.32 to 0.54) 0.03 (20.30 to 0.39) 0.04 (20.43 to 0.32)
Body mass index (kg/m
2) 17.5 16.9 16.9
Skin prick test positive (n) 35 41 36
Duration of symptoms (months{) 12.8 (1.1 to 70.5) 11.3 (2.0 to 76.4) 11.7 (3.0 to 70.8)
Wheeze ever (n) 35 42 33
Asthma symptom score (0–10){ 1.5 (0.0 to 5.5) 1.7 (0.0 to 4.5) 1.9 (0.0 to 5.7)
Rescue medication, dose/24 h{ 0.47 (0 to 4.0) 0.55 (0 to 3.7) 0.68 (0 to 2.8)
Morning PEF rate (l/min){ 182 (78 to 301) 176 (68 to 313) 184 (94 to 363)
Morning PEF (% predicted value){ 76 (43 to 105) 77 (42 to 112) 79 (54 to 107)
FEV1 (L{) 1.43(0.89 to 2.15) 1.32 (0.72 to 2.36) 1.37 (0.63 to 2.45)
FEV1 (%{ predicted value) 87 (57 to 111) 82 (52 to 107) 83 (57 to 107)
FVC (% predicted value) 90 (64 to 112) 87 (57 to124) 89 (56 to 120)
*Values are means with range in parentheses, unless otherwise stated; {no correlation between duration of the symptoms and FEV1. {Data from the run-in period.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; PEF, peak expiratory flow rate.
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for the DSCG group (continuous budesonide and DSCG;
p=0.03).
At 6 months, the mean number of asthma-free days increased
more in budesonide group than in the DSCG group (table 3).
During months 7–18, the mean number of symptom-free days
increased significantly in the continuous budesonide group
compared with the DSCG group.
During the first 6 months, compared with the run-in period,
both budesonide groups used significantly less rescue terbuta-
line (20.29 doses/day) than the DSCG group (20.07 doses/day)
(p=0.012). During months 7–18, the decline was –0.29 doses/
day in the continuous budesonide group, 20.22 doses/day in the
budesonide/placebo group and 20.18 doses/day in the DSCG
group, with no significant differences between the groups.
From baseline to 6 months, the mean standing–height
velocity in the budesonide groups was 2 cm/year slower than
in the DSCG group (p,0.001). From 7 to 18 months, height
velocity increased in both budesonide groups, with the mean
height velocity being greater for the budesonide/placebo group
(ie, during placebo) than the continuous budesonide group (6.2
versus 5.6 cm; p=0.016). After 18 months of treatment,
children receiving DSCG had grown, on average, 1.0 cm more
than children in the continuous budesonide group (8.8 versus
7.8 cm; p=0.008) and 0.6 cm more than children in the
budesonide/placebo group (ie, during placebo) (8.8 versus
8.2 cm; p=0.048). Development of standing height is presented
as standard deviation scores (SDS) in fig 4. No significant
differences in body mass index were observed between
treatment groups at any time point.
DISCUSSION
The artificial nature of the research protocol in our study, as in
many other asthma studies with drug interventions, does not
pay attention to the evolution of individual disease. Exclusion
criteria used in this study affect the selection of children. During
the study, the selection was further affected by the withdrawal
criteria. Furthermore, a ‘‘true’’ placebo group is impossible to
arrange because asthma exacerbations cannot be left untreated,
and glucocorticoids used for the treatment of exacerbations
might influence the individual evolution of asthma.
We consider that, clinically, the dominant phenotype of the
children examined is mild persistent asthma according to the
present guidelines. Some children with moderate persistent
asthma were included, as consecutive patients fulfilling the
inclusion criteria were allocated to the treatment groups.
Within the treatment groups, every patient received fixed doses
for a predetermined time despite the individual phenotype of
asthma. However, in our study, the treatment regimen could be
modified individually by 2-week courses of budesonide given as
needed.
Cessation of inhaled budesonide maintenance treatment has
previously been shown to result in a worsening of the disease
and a decline in lung function in children with persistent
moderate to severe asthma.
22 In the present study of newly
detected mild persistent asthma, a proportion of children had a
low number of exacerbations during this intermittent treatment
with budesonide. The exacerbation rate during months 7 to 18
in this budesonide/placebo group was similar to that of the
DSCG group. In the present study, two weeks’ budesonide
given when needed, after the initial regular treatment with
budesonide, seems to produce an anti-exacerbation effect
comparable with the continuous use of DSCG. However, most
withdrawals in the DSCG were early, in contrast to late
Table 2 Number of exacerbation episodes
Treatment No of patients analysed* Exacerbations/patient** (95% CI) p Value
Months 1–6
Budesonide 115 0.32 (0.22 to 0.46)
DSCG 60 1.24 (0.95 to 1.63) ,0.001
Months 7–18
Bud/Bud 57 0.97 (0.70 to 1.34)
Bud/placebo (Budesonide as needed) 58 1.69 (1.31 to 2.18)
DSCG 51 1.58 (1.20 to 2.08)
Bud/Bud vs Bud/placebo 0.008
Bud/Bud vs DSCG 0.023
Bud/placebo vs DSCG 0.728
*The total effective number of patients analysed. **The mean number of exacerbations divided by the number of patients in the group.
Bud, budesonide.
Figure 3 Kaplan–Meier plot of the time to first exacerbation for the
continuous budesonide (O, n=57), budesonide/placebo (%, n=58)
and disodium cromoglycate (D, n=60) treatment groups during the 18-
month study. The median time to the first exacerbation was significantly
longer for both the continuous budesonide (344 days) and the
budesonide/placebo (268 days) groups compared with the DSCG group
(78 days) (p,0.001 for each). The vertical line indicates the time point
(180 days) when budesonide treatment was changed to the low-dose
regimen or to placebo. After 180 days, the median time to the next
exacerbation was 233 days for the continuous budesonide group,
138 days for the budesonide/placebo group and 131 days for the DSCG
group (continuous budesonide and DSCG; p=0.03).
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groups. This might select more mild phenotypes of asthma to
the DSCG group for the last 12 months of treatment and
artificially improve the results of DSCG compared with placebo
or low-dose budesonide treatments.
While treatment of patients in the DSCG group was open,
exacerbations were diagnosed and treated in the same way as in
the other two treatment groups. Treatment in the DSCG group
was not associated with measurable systemic effects. However,
it was associated with the highest number of asthma exacer-
bations and withdrawals from the study. The initially high
number of exacerbations suggests that DSCG is not suitable to
start treatment of newly detected childhood asthma.
No significant differences between treatment groups were
observed in the morning PEF values at any time point during the
study. This suggests that morning PEF is not a very sensitive
efficacy parameter in long-term studies in children with mild
asthma as suggested previously.
7 During the first 6 months of
the study, FEV1 in litres improved significantly more in the
budesonide groups than in the DSCG group. However, at the
end of the study the differences in FEV1 disappeared despite
significant differences in the number of exacerbations. This is in
agreement with previous observations of changes in FEV1 in
litres between the treatments with budesonide, nedocromil and
placebo.
7 The use of FEV1 values measured in litres has been
recommended because predicted values depend on height,
which may be affected by ICS.
7
Our results confirm previous observations of a small initial
decline in height velocity during treatment with ICS used at
comparable doses, followed by normal height velocity.
7 Decline
in height velocity without catch-up growth has been recently
observed even during regular low ICS dosage.
8 However,
another study suggests that children treated regularly with
budesonide attain their predicted final adult height.
23 In the
present study, height velocity was dose-related; during the low-
dose budesonide and placebo treatments, the systemic effect of
the initial high-dose budesonide were reduced. In the present
18 months follow-up study, standing height velocity was
normalised during low-dose budesonide treatment within
1 year of commencement of treatment. The height velocity
increased, however, more rapidly during the placebo treatment
than during the low-dose budesonide treatment, suggesting
catch-up of the initial loss in standing height.
While long-term maintenance therapy with low-dose ICS is
recommended for mild persistent asthma,
7 8 24 25 some children
do not seem to need continuous inhaled corticosteroid treat-
ment. Advantages of this treatment strategy include a reduced
risk of ICS-related growth suppression. Intermittent courses of
inhaled or oral corticosteroids have been suggested recently for
adults with mild persistent asthma.
26
Regular use of budesonide afforded better exacerbation
control but more systemic effect than intermittent use of
budesonide given as needed or regular DSCG treatment. No
significant differences in the morning PEF and FEV1 in litres or
in asthma-free days were observed between the regular or
intermittent budesonide treatments during months 7–18. These
findings suggest that the overall anti-asthmatic effect of the
intermittent budesonide treatment might be intermediate
between the regular low-dose ICS and DSCG treatments. The
dose of ICS could be reduced as soon as asthma is controlled.
Some children do not seem to need continuous ICS treatment.
Table 3 Asthma-free days after the run-in period
Treatment
No of patients
analysed*
Mean change in asthma-free
days, % ** (95% CI) p Value
Months 1–6
Budesonide 114 +20.1 (+14.9 to +25.4)
DSCG 60 +4.1 (23.2 to +11.3) 0.001
Months 7–18
Bud/Bud 55 +29.2 (+21.2 to +37.2)
Bud/placebo
(Budesonide as
needed)
58 +19.6 (+11.8 to +27.4)
DSCG 51 +11.6 (+3.3 to +19.9)
Bud/Bud vs Bud/
placebo
0.092
Bud/Bud vs DSCG 0.003
Bud/Placebo vs DSCG 0.166
*The total effective number of patients analysed; **Mean change in asthma-free days
compared with the baseline.
Figure 4 Mean change in standing height (SDS) over the 18-month
study period for the continuous budesonide (e, n=50), budesonide/
placebo (%, n=45) and disodium cromoglycate (DSCG) (D, n=43)
treatment groups. 1–6 months, both budesonide groups versus DSCG,
p,0.001; 7–18 months, continuous budesonide group versus
budesonide/placebo group, p=0.016. Note the fast height velocity
during months 7–18 in the budesonide/placebo group.
What is already known on this topic
It is still debated whether mild asthma in adults needs regular
treatment with inhaled corticosteroids.
What this study adds
Some children who achieve good initial control of their mild
asthma does not seem to need continuous treatment with inhaled
corticosteroids.
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